http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Baxter and bioMérieux Announce Collaboration to Improve Identification and Treatment of Acute Kidney Injury
-
Baxter to Host First Quarter 2019 Financial Results Conference Call for Investors
-
Baxter (BAX) Announces U.S. FDA Approval and Launch of Ready-to-Use Cardiovascular Medicine Eptifibatide
-
Baxter Announces U.S. FDA Approval and Launch of Ready-to-Use Cardiovascular Medicine Eptifibatide
-
Baxter Honored as a 2019 “Top Company for Executive Women” by the National Association for Female Executives
-
Baxter Declares Quarterly Dividend
-
Baxter to Present at the Barclays Global Healthcare Conference
-
Baxter and NantHealth® Advance Digital Health Technology for Medical Devices in the Hospital ICU
-
Baxter to Present at the Raymond James 40th Annual Institutional Investors Conference
-
Baxter Reports 2018 Fourth-Quarter and Full-Year Results
-
Baxter to Present at the 8th Annual SVB Leerink Global Healthcare Conference
-
Baxter Announces 5 Million Home Dialysis Treatments Managed Globally with Sharesource Remote Patient Management
-
Baxter (BAX) Commences U.S. Clinical Trial for on-Demand Peritoneal Dialysis Solution System
-
Baxter Starts U.S. Clinical Trial for on-Demand Peritoneal Dialysis Solution System
-
Baxter to Host Fourth Quarter 2018 Financial Results Conference Call for Investors
-
Baxter Launches Curved Applicator for Floseal, Expanding Use of Leading Hemostat During ENT Procedures
-
Baxter Supports New EFCNI Standards in Newborn Care in Raising Awareness of Risks from Malnutrition
-
Baxter (BAX) Announces Patricia Morrison and Amy Wendell to Board
-
Baxter Appoints Patricia Morrison and Amy Wendell to Its Board
-
Baxter to Present at the 37th Annual J.P. Morgan Healthcare Conference
-
Prescient Surgical Raises $10 Million in Series B Investment
-
Baxter Unveils New Products at the ASMBS – Obesity Week Meeting to Help Surgeons Overcome Challenges During Bariatric Surgery
-
Baxter Declares Quarterly Dividend and Announces Expanded Share Repurchase Authorization
-
Baxter Highlights Data at ISPOR Europe 2018 on Clinical and Economic Benefits When Addressing Malnutrition, Intraoperative Bleeding
-
Baxter Introduces New Tisseel Prima Syringe at 2018 American Association of Gynecologic Laparoscopists Meeting
-
Baxter to Present at Citi’s 2018 Global Healthcare Conference
-
Baxter Reports Third-Quarter 2018 Results and Updates Financial Outlook for Full-Year 2018
-
Baxter Highlights Clinical Data at ASN: Kidney Week Showing How New Technologies Are Advancing Dialysis Care across Modalities
-
Baxter (BAX) Receives CE Mark for PrisMax
-
Baxter Receives CE Mark for PrisMax, the Next-Generation System for Continuous Renal Replacement and Organ Support Therapies
-
Baxter Announces U.S. Regulatory Filing for PrisMax Acute Care System and Presentation of 15 Abstracts to Start ASN: Kidney Week 2018
-
Baxter to Showcase Critical Care Innovation at the 2018 European Society of Intensive Care Medicine Congress
-
Baxter and ASPEN Launch “SmartPN” Tools to Reinforce Appropriate Use of Parenteral Nutrition
-
Baxter to Present at the 27th Annual Credit Suisse Healthcare Conference
-
Baxter and Mayo Clinic Announce Collaboration to Establish Renal Care Center of Excellence in the U.S.
-
Baxter Collaborates with University of Southern California Center for Body Computing to Advance Digital Health Solutions
-
Baxter (BAX) Reports Publication of New Data on Floseal Surgical Hemostat Quantifying Clinical & Healthcare Resource Outcomes in Spine
-
New Data on Floseal Surgical Hemostat Quantifies Clinical and Healthcare Resource Outcomes in Spine Surgery Cases
-
Baxter (BAX) Reports FDA Clearance of ALTAPORE Bioactive Bone Graft in Posterolateral Spine Surgery
-
Baxter Announces U.S. FDA Clearance of ALTAPORE Bioactive Bone Graft in Posterolateral Spine Surgery
-
Baxter Recognized as One of Working Mother’s 2018 ‘100 Best Companies’
-
Baxter to Host Third Quarter 2018 Financial Results Conference Call for Investors
-
Baxter Named to Dow Jones Sustainability Index for 19th Consecutive Year, Recognized for Its Dedication to Corporate Responsibility
-
Baxter (BAX) Reports FDA Clearance of Actifuse Flow Bone Graft Substitute for Use in Variety of Orthopedic & Surgical Procedures
-
Baxter Announces U.S. FDA Clearance of New Bone Graft Substitute, Actifuse Flow
-
Baxter Unveils Olimel 7.6% High Protein Parenteral Nutrition Formulation at the 2018 ESPEN Congress
-
Baxter (BAX) Announces CE Mark and Regulatory Approval of New Evo IQ Infusion System
-
Baxter Announces CE Mark and Regulatory Approval of New Evo IQ Infusion System for the United Kingdom, Ireland, Australia and New Zealand
-
Baxter Reports Second-Quarter 2018 Results and Increases Earnings Outlook for Full-Year 2018
-
Baxter Declares Quarterly Dividend

